Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

Recruiting

Phase 1

Phase 2

CAPTEMOral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

Sponsor:

Northwell Health

Code:

NCT03213002

Conditions

Glioblastoma Multiforme (GBM)

Glioblastoma

Glioma of Brain

Glioblastoma, Adult

Brain Tumor

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Capecitabine

Temozolomide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-17. This information was provided to ClinicalTrials.gov by Northwell Health on 2025-04-09.